Clinical trial NCT05038748: A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected Siblings
Official title: A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Autism Spectrum Disorder
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-09-09
Enrollment: 150
Sex: ALL
Minimum age (years): 7
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The cohort was established at the Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.

Brief summary: The primary aims are to identify important gut microbiota signatures for youth with ASD, to identify dysbiosis features for different levels of ASD features and clinical courses, to search the possibility to intervene the disease course if we can tease out the dysbiosis responsible for the flare-up and improvement of the symptoms of the disease. The secondary aims are to identify the clinical and neuropsychological measures that are associated with direct and indirect regulation or interactions from gut-brain axis signaling, and based our preliminary results on reducing the measures for future large-scale microbiome study in ASD.

Detailed description: Background: Despite increased public awareness of autism spectrum d isorder (ASD) and extensive research on this neurodevelopmental disorder in the past decades, the underlying mechanisms of ASD remain unclear, and ASD is still recognized as having the highest disease and care burden among child psychiatric disorders regarding its long-term impairment across the lifespan. Hence, identifying the biomarkers for early detection and effective biological treatments for ASD is among the most challenging tasks all over the world. The concerns about physical comorbidities such as immune dysregulation, allergy, and gastrointestinal issues, etc. emerged in the recent decade. Hence, the new perspective of searching for the underlying mechanism for ASD also targets the associations between microbiota and ASD. However, despite many microbiome studies in ASD, they provided limited knowledge about the specific link that particular imbalance gut bacteria could affect the behavioral deficits in ASD because lack of consideration of the clinical and genetic heterogeneity of ASD. With only a few studies examining the well-defined ASD-related impairments, the GI system dysfunction, and the microbiomes, the associations among ASD-related symptoms, GI symptoms, and microbiota remain indistinct. Therefore, the investigators propose this pilot study to fill the gap between the potential role of microbiome as a biomarker for ASD to facilitate developing the treatment for ASD.

Method and material: The case-sibling control study design will be used to investigate microbiome in 60 probands with ASD, aged 7-25 yrs old, and 30 unaffected siblings either from the PI Gau's ASD cohort or the Department of Psychiatry, National Taiwan University Hospital. The parents of all the subjects will receive the Autism Diagnostic Interview-Revised (ADI-R) interviews and report on the questionnaires regarding autistic symptoms, emotional/behavioral problems, social functions, G-I symptoms, and life quality. The ASD and sibling subjects will receive the Autism Diagnostic Observation Scale and neuropsychological tasks. The experiment of microbiome will be conducted by the core lab of microbiome (co-PI Ni) at the college of medicine, National Taiwan University. The data analyses will combine microbiomics and the extensive behaviors/cognitive function variables to establish an objective potential pipeline.

Anticipated outcome: With the accomplishment of this project, the investigators will establish the comprehensive yet fewer bios for the ASD risk bio-factors in Asia, and provide the potential clinical interview and assessments related to GI symptoms regulated by microbiota. The potential biomarkers may be further used to developing the treatment for ASD.

Significance: Several features of this project constitute its significance: a wealth of measures of ASD phenotypes (valid phenotype), ASD as a catastrophic disease (importance), the first ASD study with unaffected sibling design for microbiomics studies in ASD (originality), and new approaches and technologies (novelty) for searching microbiomics in ASD.

Eligibility criteria: Inclusion Criteria:

* a clinical diagnosis of ASD defined by the DSM-IV confirmed by ADI-R or ADOS and also clinical reappraisal based on the newly release DSM-5 criteria for ASD
* ages range from 7 to 25 at the time now
* at least one biological parent
* parents that are both Han Chinese in Taiwan

Exclusion Criteria:

* intellectual disability
* epilepsy
* ADHD
* autoimmune diseases

Primary outcomes:
measure: Autism Diagnostic Interview-Revised (ADI-R)
timeFrame: 1 hour
measure: Autism Diagnostic Observation Scale (ADOS)
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan Univeristy Hospital
Study officials:
References: